Skip to main content
SpringerLink
Log in

Resource Utilisation and Time Commitment Associated with Correction of Anaemia in Cancer Patients Using Epoetin Alfa

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Objective: This study set out to identify the resource use and time commitment associated with treatment of anaemia with erythropoietic therapy, for both haematology/oncology clinics and patients.

Methods: The study was carried out at three haematology/oncology clinics in the US, and included 124 cancer patients with anaemia. Stages in the administration of epoetin alfa were identified (preparation, injection and documentation). At each site a trained researcher observed medical staff and recorded the time taken for each stage, in minutes, using a stopwatch. The supplies used for each stage were also recorded. Travel times, waiting times and demographics for patients and caregivers attending the clinic were obtained from self-report questionnaires during the clinic visit. In total, 177 injections of epoetin alfa were administered.

Main outcome measure: Total mean time clinic staff and patients spent on treatment visits.

Results: The total mean time expended by clinic staff for each injection, including preparation, administration, documentation and phlebotomy, was 25.5 minutes (range 18.6–31.2 at individual centres). The total mean time requirement for patients (time spent travelling to and from the clinic, time spent waiting for the epoetin alfa injection) was 83 minutes.

Conclusion: Treatments that may reduce the time burden of anaemia management should be considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Tchekmedyian NS. Anemia in cancer patients: significance, epidemiology, and current therapy. Oncology 2002 Sep; 16(9 Suppl. 10): 17–24

    PubMed  Google Scholar 

  2. Koeller JM. Clinical guidelines for the treatment of cancerrelated anemia. Pharmacotherapy 1998 Jan–Feb; 18(1): 156–69

    PubMed  CAS  Google Scholar 

  3. Spivak JL. Cancer-related anemia: its causes and characteristics. Semin Oncol 1994 Apr; 21(2 Suppl. 3): 3–8

    PubMed  CAS  Google Scholar 

  4. Thomas ML. Anemia and quality of life in cancer patients: impact of transfusion and erythropoietin. Med Oncol 1998 Aug; 15Suppl. 1: S13–8

    PubMed  Google Scholar 

  5. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997 Jul; 34(3 Suppl. 2): 13–9

    PubMed  CAS  Google Scholar 

  6. Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997 Feb; 13(2): 63–74

    Article  PubMed  CAS  Google Scholar 

  7. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002 Aug; 94(16): 1211–20

    Article  PubMed  CAS  Google Scholar 

  8. Vansteenkiste J, Rossi G, Foote M. Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia. Expert Opin Biol Ther 2003 Jun; 3(3): 501–8

    Article  PubMed  CAS  Google Scholar 

  9. Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003 Apr; 14(4): 511–9

    Article  PubMed  CAS  Google Scholar 

  10. Cella D, Zagari MJ, Vandoros C, et al. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic patients when referenced to the general population. J Clin Oncol 2003 Jan; 21(2): 366–73

    Article  PubMed  Google Scholar 

  11. Smith Jr RE, Tchekmedyian NS, Chan D, et al. A dose-finding and schedule-finding study of darbepoetin alfa for the treatment of chronic anaemia of cancer. Br J Cancer 2003 Jun; 88(12): 1851–8

    Article  PubMed  CAS  Google Scholar 

  12. Cremieux PY, Finkelstein SN, Berndt ER, et al. Cost effectiveness, quality-adjusted life-years and supportive care: recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoeconomics 1999 Nov; 16 (5 Pt 1): 459–72

    Article  PubMed  CAS  Google Scholar 

  13. Fortner B, Tauer K, Zhu L, et al. The impact of medical visits for chemotherapy-induced anemia and neutropenia on the patient and caregiver: a national survey. Commun Oncol 2004 1(4): 211–7

    Article  Google Scholar 

  14. Houts AC, Loh GA, Fortner BV, et al. Patient and caregiver time burden associated with anaemia treatment in different patient populations. Support Care Cancer. Epub 2006 May

  15. Canby IV JB. Applying activity-based costing to healthcare settings. Health Financ Manage 1995 Feb; 49(2): 50–2,54-6

    Google Scholar 

  16. Gabram SG, Mendola RA, Rozenfeld J, et al. Why activitybased costing works. Physician Exec 1997 Jul–Aug; 23(6): 31–7

    PubMed  CAS  Google Scholar 

  17. Meehan KR, Matias CO, Rathore SS, et al. Platelet transfusions: utilization and associated costs in a tertiary care hospital. Am J Hematol 2000 Aug; 64(4): 251–6

    Article  PubMed  CAS  Google Scholar 

  18. Cantor SB, Hudson DV, Lichtiger B, et al. Costs of blood transfusion: a process-flow analysis. J Clin Oncol 1998; 16(7): 2364–70

    PubMed  CAS  Google Scholar 

  19. Cremieux PY, Barrett B, Anderson K, et al. Cost of outpatient blood transfusion in cancer patients. J Clin Oncol 2000; 18(14): 2755–61

    PubMed  CAS  Google Scholar 

  20. Meadowcroft AM, Gilbert CJ, Maravich-May D, et al. Cost of managing anemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy. Am J Health Syst Pharm 1998 Sep; 55(18): 1898–902

    PubMed  CAS  Google Scholar 

  21. Barnes R. Motion and time study: design and measurement of work. New York: John Wiley & Sons, 1980

    Google Scholar 

  22. Beveridge RA, Rifkin RM, Moleski RJ, et al. Impact of longacting growth factors on practice dynamics and patient satisfaction. Pharmacotherapy 2003 Dec; 23 (12 Pt 2): 101S–9S

    Article  PubMed  CAS  Google Scholar 

  23. Siegel JE, Torrance GW, Russell LB, et al. Guidelines for pharmacoeconomic studies: recommendations from the panel on cost effectiveness in health and medicine. Pharmaco- economics 1997 Feb; 11(2): 159–68

    Article  CAS  Google Scholar 

  24. Schwartzberg LS, Yee LK, Senecal FM, et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004; 9(6): 696–707

    Article  PubMed  CAS  Google Scholar 

  25. Patton J, Reeves T, Wallace J. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist 2004; 9(4): 451–8

    Article  PubMed  CAS  Google Scholar 

  26. Cella D, Kallich J, McDermott A, et al. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004 Jun; 15(6): 979–86

    Article  PubMed  CAS  Google Scholar 

  27. Ortega A, Dranitsaris G, Puodziunas AL. What are cancer patients willing to pay for prophylactic epoetin alfa? A costbenefit analysis. Cancer 1998 Dec; 83(12): 2588–96

    Article  PubMed  CAS  Google Scholar 

  28. Gabrilove J, Einhorn L, Livingston R, et al. Once-weekly dosing of epoetin alfa is similar to three-times weekly dosing in increasing hemoglobin and quality of life [abstract]. Proc Am Soc Clin Oncol 1999; 18(574a): 2216

    Google Scholar 

Download references

Acknowledgements

The authors thank Parthiv J. Mahadevia, Gale Harding and Josephine Mauskopf of MEDTAP International, Inc., Bethesda, MD, USA for their contributions to the design and management of the study; Amgen Inc., Thousand Oaks, CA, USA for financial assistance; and Gardiner-Caldwell London, Maidenhead, UK for editorial assistance.

Joel Kallich is an employee of Amgen Inc., and Robert Smith has received research grants, is part of a speakers bureau, and a member of an advisory board for Amgen.

Author information

Authors and Affiliations

  1. Bone Marrow Transplant Program, Section of Hematology/Oncology, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, New Hampshire, 03756, USA

    Kenneth R. Meehan

  2. Pacific Shores Medical Group, Long Beach, California, USA

    N. Simon Tchekmedyian

  3. South Carolina Cancer Center, Columbia, South Carolina, USA

    Robert E. Smith

  4. Amgen Inc., Thousand Oaks, California, USA

    Joel Kallich

Authors
  1. Kenneth R. Meehan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Simon Tchekmedyian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert E. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joel Kallich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth R. Meehan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meehan, K.R., Simon Tchekmedyian, N., Smith, R.E. et al. Resource Utilisation and Time Commitment Associated with Correction of Anaemia in Cancer Patients Using Epoetin Alfa. Clin. Drug Investig. 26, 593–601 (2006). https://doi.org/10.2165/00044011-200626100-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200626100-00006

Keywords

Search

Navigation